We would love to hear your thoughts about our site and services, please take our survey here.
All part of their MO, last week they were increasing daily volumes by up to 7x all designed to suck in more unsuspecting punters. This share really typifies the AIM market as the wild west of investing where only the bods and MM make money.
Seems to be a vast number of products out there already, check out Sulforaphane Supplement 405mg Complex on Amazon. Admittedly Evgen have a concentrated pill, but there is nothing stopping any large pharmaceutical company using Sulforaphane to develop their own remedy. That's probably why the share price has been on a downward spiral for years.
Or maybe it's jobs for the boys, in the great merry go round and that's why they all hold so many positions. You scratch my back I'll scratch yours and all funded by the shareholders, who's holding is depreciating by the day. That's what I'm seeing
The company is certainly splashing the cash on appointments, they'll need a new share issue just to fund the salaries. Employing Ferrari mechanics to service an Austin Allegro comes to mind.
I think you're right radar, not so sure about the jolly old chap though.
You'll probably find Evgen's broker will be fully aware of any new dilution and position themselves accordingly. Looking at the price action the last time it was pretty obvious they were closely working with the bods. A flurry of positive news followed by a sell off.
You could play them at the same game, liquidate half your position on good news, you'll then have the funds to buy the new shares at a lower price and possibly pick up more than your entitled allowance. Just a thought to limit the damage caused by a share dilution.
I wouldn't base too much on what AI is saying.
Unless they have a miracle breakthrough in the next few months a share dilution is inevitable.
I would expect a flurry of positive news from the bods leading up to this, promising the earth with all their new collaborations but this is all talk to entice new investors
The point I was trying to make was that having dealt with the complexities of an autistic child at first hand, I can't believe Evgen let alone anyone else is anywhere near to finding any kind of cure.
I would love to be proved wrong, but again, snake oil comes to mind.
Wow, they have certainly come out with all guns blazing. Are these genuine investors or a company employed to smooth the path for the next share dilution. Most investors after having gone through the ringer and lost so much would be actively expressing their annoyance. Little surprised with the die hard following, I wonder at what point capitulation sets in. Still a share dilution is on its way and the board will be desperate to say and do anything to get the price up. Here's an idea, why don't they personally financially back their over optimisam on this company.
As the severity of the share dilution is pretty much all riding on Stalicla coming out trumps, and the odds of it happening at around 12%, I really can't see me losing my " I'm always right" title any time soon.
Focus your anger on the bods who have presided over an 80% price drop in the last 2 years .
The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%–20%, and it has not changed during the past few decades. Therefore, pharmaceutical companies are under pressure to select one compound, among many others, with a high probability of success. The differences in drug features affect their probabilities of approval success. In this study, we examined the approval success rates of drug candidates, developed in the United States, the European Union, or Japan, by focusing on four parameters (“drug target,” “drug action,” “drug modality,” and “drug application”) and their combinations, and identified factors that conditioned the outcome of the drug development process. We obtained a total success rate of 12.8%, after evaluating 3999 compounds. Moreover, after analyzing the combinations of these parameters, the approval success rates of drugs that corresponded to the following categories—a stimulant in drug action or an enzyme in drug target and biologics (excluding monoclonal antibody) in drug modality—were high (34.1% and 31.3%, respectively). Univariate and multivariate logistic regression analyses revealed that stimulant in drug action, and “B” (blood and blood forming organs), “G” (genito-urinary system and sex), and “J” (anti-infectives for systemic use) in drug application were statistically associated with high approval success rates. We found several parameters and their combinations that affected drug approval success rates. Our results could assist pharmaceutical companies in evaluating the probability of success of their drug candidates and, thus, in efficiently conducting the clinical development process.
It does all seem very strange, they just seem out of favour at the moment. Is the market pricing in this new FSA derivative and the effect it will have on the NIM. That, together with increased provisions for bad debts could all eat into longer term profitability hence the sell off.
One thing is for certain, they are still making billions, and the share buybacks, not a fan but it does help the balance sheet and dividends keep rolling in. Eventually it will turn.
Bob, where are you getting those odds from.
You'll find that they are closer to 99/1 with this type of research.
Sorry to say but this is a sell into any rally. With the share placement hanging over this and no imminent cash coming through it's only a matter of time before these start heading south again.
DYOR, and don't get suckered in with all the hype.
CJ39 I think we should call it a day, we've expressed our views and hopefully some have taken it on board. You'll probably find the die hards on here are financially way to deep into this, and it just wouldn't make sense to cut their position as there is little left to get back. Hope of some transformational news is all they have left.
I do genuinely hope things turn around for the remaining holders, but I remain sceptical.
Time will surely tell who was right or wrong.
If he does, they'll only be worth around £10,000 after the share dilution.
Baf3 what a daft comment, there are literally 1,000s of companies out there pursuing the same goals, and probably just as many that have gone under because their product just didn't work. Huw 's latest casualty is a prime example.
If you are trying to stick moral label on this, maybe take your concerns up with the bods, let's face it their extortionate salaries are hardly adding any longevity or value to the company.
What ever anyone says on this site, they are all sitting on a loss. I feel for Kight, he is sitting on a paper loss of 700k. I wonder if he has told his partner, wouldn't want to be in that household. Only winners are the bods with their extortionate salaries, roles that they only seem to be doing part time looking at all their other positions.
I wonder if any of them post on these sites, looking at some of the ultra positive posts even after this disastrous share price move I wouldn't be surprised.
The way to look at this share is similar to a never ending TV series that is past its best, the final few series of the walking dead come to mind.
They give you just enough to hook you into subscribing for another season which again disappoints. A placement is inevitable around February/ March time, the incentive is the Stalica payments which I personally don't think will ever materialise. They will not risk leaving it to the last minute, as just before the last placement, expect a flurry of positive news at how wonderful things are, but the true litmus test is have the bods bought in
I care because I don't want unsuspecting investors sucked in by all the biased dribble that emanates from this site and from the bods themselves.
The shares have dropped around 80% since Huw has taken over, never once has he publicly apologised. He says they can't buy for legal reasons which inturn sucks in more punters because they think something big is about to be announced.Our CEO is great and has a track record, if you care to look on company house, of being at the helm of failed companies. This is my opinion so please do your own research.